TG Therapeutics reported second-quarter 2026 revenue of $240.34 million [2] during an earnings report released this week.
The results signal a significant scaling phase for the Morrisville, North Carolina, company as it converts clinical success into commercial market share. The growth is primarily attributed to the performance of its drug, BRIUMVI, which has become the primary driver of the firm's financial expansion.
Revenue for the quarter ended June 30, 2026, represented a 70.3% increase [2] compared to the same period a year earlier. BRIUMVI contributed $228 million [1] to that total, reflecting a 70% increase [8] in revenue for the specific drug.
Despite the top-line growth, earnings per share for the second quarter were $0.05 [4], a decrease from the $0.17 [5] reported in the same quarter of the previous year. The company reported a net income of $7.8 million [6] for the period.
Based on the second-quarter momentum, TG Therapeutics updated its financial outlook for the remainder of the year. The company raised its full-year 2026 revenue guidance to $950 million [8].
The company's headquarters in North Carolina continues to oversee the commercial rollout of its portfolio as it manages the costs associated with rapid scaling. While the EPS has dipped year-over-year, the substantial jump in total revenue suggests a growing patient base for BRIUMVI.
“TG Therapeutics reported second-quarter 2026 revenue of $240.34 million”
The discrepancy between soaring revenue and declining earnings per share suggests that TG Therapeutics is investing heavily in the commercialization and distribution of BRIUMVI. By raising its full-year guidance to $950 million, the company is signaling confidence that its market penetration is accelerating faster than its operational expenses are growing.
